T Todisco1, S Mastromattei1, L Chioma2, G Ubertini1, M G Pattumelli1, D Fintini1, M Cappa1. 1. Endocrinology Unit, University Pediatric Department, Bambino Gesù Children's Hospital, IRCCS, P.zza Sant'Onofrio 4, 00165, Rome, Italy. 2. Endocrinology Unit, University Pediatric Department, Bambino Gesù Children's Hospital, IRCCS, P.zza Sant'Onofrio 4, 00165, Rome, Italy. laura.chioma@opbg.net.
Abstract
PURPOSE: Constitutional delay of growth and puberty (CDGP) represents the most frequent cause of delayed puberty in males, sharing some clinical features with growth hormone deficiency (GHD) and isolated hypogonadotropic hypogonadism (IHH). Short-term induction therapy (SIT) has been approved for the induction of puberty in CDGP. We aim to investigate the efficacy of SIT with transcutaneous testosterone gel (TTG) or intramuscular testosterone therapy (IMTT) in a cohort of CDGP subjects, compared to clinical observation. Furthermore, we aim to evaluate the role of SIT as a diagnostic tool to differentiate CDGP from GHD and IHH subjects. METHODS: The retrospective study included 246 male subjects with delayed puberty. The study population was divided into three groups: TTG, IMTT, and control group (CNT). RESULTS: At 6 months observation, height velocity (HV) was significantly increased in both treated groups compared to CNT group, particularly higher in TTG than IMTT group. A significant testicular enlargement was revealed in both CNT and TTG group compared to IMTT group. Furthermore, LH value was significantly greater in TTG compared to IMTT group. IGF-1 values after SIT rose significantly in both treated groups compared to CNT group. Moreover, almost all GH provocative tests performed after SIT showed a normal GH response. CONCLUSION: SIT with TTG appears to be more effective to induce growth spurt, better tolerated and with a more physiological effect on pubertal induction compared to IMTT in CDGP population. Finally, TTG might be a useful tool in the diagnostic work up to discriminate CDGP from GHD or IHH.
PURPOSE: Constitutional delay of growth and puberty (CDGP) represents the most frequent cause of delayed puberty in males, sharing some clinical features with growth hormone deficiency (GHD) and isolated hypogonadotropic hypogonadism (IHH). Short-term induction therapy (SIT) has been approved for the induction of puberty in CDGP. We aim to investigate the efficacy of SIT with transcutaneous testosterone gel (TTG) or intramuscular testosterone therapy (IMTT) in a cohort of CDGP subjects, compared to clinical observation. Furthermore, we aim to evaluate the role of SIT as a diagnostic tool to differentiate CDGP from GHD and IHH subjects. METHODS: The retrospective study included 246 male subjects with delayed puberty. The study population was divided into three groups: TTG, IMTT, and control group (CNT). RESULTS: At 6 months observation, height velocity (HV) was significantly increased in both treated groups compared to CNT group, particularly higher in TTG than IMTT group. A significant testicular enlargement was revealed in both CNT and TTG group compared to IMTT group. Furthermore, LH value was significantly greater in TTG compared to IMTT group. IGF-1 values after SIT rose significantly in both treated groups compared to CNT group. Moreover, almost all GH provocative tests performed after SIT showed a normal GH response. CONCLUSION: SIT with TTG appears to be more effective to induce growth spurt, better tolerated and with a more physiological effect on pubertal induction compared to IMTT in CDGP population. Finally, TTG might be a useful tool in the diagnostic work up to discriminate CDGP from GHD or IHH.
Keywords:
Constitutional delay of growth and puberty; Delayed puberty in boys; Growth retardation in adolescent boys; Injective testosterone therapy in adolescence; Short-term induction therapy; Transdermal testosterone gel
Authors: Andrea Messina; Fanny Langlet; Konstantina Chachlaki; Juan Roa; Sowmyalakshmi Rasika; Nathalie Jouy; Sarah Gallet; Francisco Gaytan; Jyoti Parkash; Manuel Tena-Sempere; Paolo Giacobini; Vincent Prevot Journal: Nat Neurosci Date: 2016-05-02 Impact factor: 24.884
Authors: Marcia E Herman-Giddens; Jennifer Steffes; Donna Harris; Eric Slora; Michael Hussey; Steven A Dowshen; Richard Wasserman; Janet R Serwint; Lynn Smitherman; Edward O Reiter Journal: Pediatrics Date: 2012-10-20 Impact factor: 7.124